Epion Therapeutics Initiates Phase 3 Clinical Trials for Minimally-Invasive Keratoconus Treatment
BURLINGTON, Mass.--(BUSINESS WIRE)--Epion Therapeutics (Epion) announced the commencement of its Phase 3 Apricity trials for EpiSmart™, the company’s minimally-invasive keratoconus therapy. This marks a milestone in the company's mission to redefine the treatment of keratoconus. EpiSmart is an investigational drug-device combination indicated for epithelium-on cross-linking to treat keratoconus upon initial diagnosis. Keratoconus is a bilateral progressive corneal disorder which causes permanen